NasdaqGM:KALV

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has KalVista Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KALV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

13.4%

KALV

-3.0%

US Biotechs

-1.3%

US Market


1 Year Return

47.0%

KALV

33.9%

US Biotechs

18.5%

US Market

Return vs Industry: KALV exceeded the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: KALV exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

KALVIndustryMarket
7 Day13.4%-3.0%-1.3%
30 Day27.6%1.8%5.3%
90 Day35.2%-3.7%7.5%
1 Year47.0%47.0%36.2%33.9%21.3%18.5%
3 Year25.2%25.2%19.1%13.1%42.4%32.9%
5 Yearn/a15.2%7.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is KalVista Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is KalVista Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.07x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: KALV ($16.95) is trading above our estimate of fair value ($3.03)

Significantly Below Fair Value: KALV is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: KALV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: KALV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KALV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KALV is overvalued based on its PB Ratio (4.1x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is KalVista Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

61.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KALV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KALV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KALV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KALV's revenue (65.1% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: KALV's revenue (65.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KALV's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has KalVista Pharmaceuticals performed over the past 5 years?

-12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KALV is currently unprofitable.

Growing Profit Margin: KALV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KALV is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare KALV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KALV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: KALV has a negative Return on Equity (-43.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is KalVista Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: KALV's short term assets ($80.2M) exceed its short term liabilities ($8.5M).

Long Term Liabilities: KALV's short term assets ($80.2M) exceed its long term liabilities ($1.0M).


Debt to Equity History and Analysis

Debt Level: KALV is debt free.

Reducing Debt: KALV has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KALV has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KALV has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 27.3% each year.


Next Steps

Dividend

What is KalVista Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KALV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KALV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KALV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KALV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KALV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Andy Crockett (45 yo)

3.92yrs

Tenure

US$1,731,162

Compensation

Mr. Thomas Andrew Crockett, also known as Andy, M.B.A., has been Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. since November 21, 2016. Mr. Crockett is the Founder of KalVista Pha ...


CEO Compensation Analysis

Compensation vs Market: Andy's total compensation ($USD1.73M) is about average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Crockett
CEO & Director3.92yrsUS$1.73m1.33%
$ 4.0m
Benjamin Palleiko
Chief Business Officer & CFO3.92yrsUS$1.03m0.18%
$ 550.9k
Christopher Yea
Chief Development Officer3.92yrsUS$926.04k0.46%
$ 1.4m
Edward Feener
Chief Scientific Officer3.92yrsUS$1.59m0.54%
$ 1.6m
Leah Monteiro
Director of Corporate Communications & Investor Relationsno datano datano data
Rachel Morten
Head of Regulatory Affairs and QAno datano datano data
Andreas Maetzel
Senior Vice President of Medical3.58yrsUS$416.74kno data
Michael Smith
Senior Vice President of Development1.42yrsno datano data
Stephen Donnelly
Director of Finance and Company Secretaryno datano datano data
John McKune
Vice President of Financeno dataUS$516.08kno data

3.9yrs

Average Tenure

54yo

Average Age

Experienced Management: KALV's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Crockett
CEO & Director3.92yrsUS$1.73m1.33%
$ 4.0m
Arnold Oronsky
Independent Director3.92yrsUS$109.92k0%
$ 0
Martin Edwards
Independent Chairman1.33yrsUS$271.38k0%
$ 0
Edward Unkart
Independent Director5.83yrsUS$109.92k0%
$ 0
Albert Cha
Independent Director3.92yrsUS$104.92k0%
$ 0
Daniel Soland
Independent Director1.5yrsUS$40.00k0.056%
$ 169.5k
Brian J. Pereira
Independent Director1.67yrsUS$47.50k0%
$ 0
Bong Koh
Board Observer5.25yrsno datano data
Tomas Kiselak
Board Observer5.25yrsno datano data

3.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: KALV's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

KalVista Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: KalVista Pharmaceuticals, Inc.
  • Ticker: KALV
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$303.533m
  • Shares outstanding: 17.91m
  • Website: https://www.kalvista.com

Number of Employees


Location

  • KalVista Pharmaceuticals, Inc.
  • 55 Cambridge Parkway
  • Suite 901 East
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KALVNasdaqGM (Nasdaq Global Market)YesNew Ordinary SharesUSUSDNov 2016
4XC1DB (Deutsche Boerse AG)YesNew Ordinary SharesDEEURNov 2016

Biography

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product port ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/21 00:08
End of Day Share Price2020/10/20 00:00
Earnings2020/07/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.